85-1960-95　CDKN2A, Recombinant, Human, TAT-tag (Cyclin-dependent Kinase Inhibitor 2A, Isoforms 1/2/3, Cyclin-dependent Kinase 4 Inhibitor A, CDK4I, Multiple Tumor Suppressor 1, MTS-1, p16-INK4a, p16-INK4, p16INK4A, CDKN2, MTS1) 25ug　149753

特徴

• p16-INK4a is a nuclear protein that regulates the cell cycle by inhibiting cyclin dependent kinase-4 (CDK4) and CDK6. p16-INK4a inhibits CDK activity by binding to the CDK molecules in a manner that interferes with their ability to interact with cyclin D. This activity has the effect of suppressing tumor formation and growth, and of inducing replicative senescence in various normal cells, including stem cells. The expression of p16-INK4a steadily increases with age and tends to accumulate in stem cell compartments. The deletion, rearrangement, or mutation of the p16-INK4a gene is frequently found in melanomas as well as in certain other types of cancer. P16-INK4a and other transcription factors have been introduced into cells by DNA transfection, viral infection, or microinjection. Protein transduction using TAT fusion proteins represents an alternative methodology for introducing transcription factors and other nuclear proteins into primary as well as transformed cells. Recombinant human p16-INK4a-TAT expressed in E. coli is a 18kD protein containing 167aa, including the 156 residues of full-length p16-INK4a and a 13-residue C-terminal TAT peptide (GGYGRKKRRQRRR).
• Source:Recombinant protein corresponding to human p16-INK4a-TAT, expressed in E.coli.
• Endotoxin:<0.1ng/ug (1EU/ug)
• AA Sequence:EPAAGSSMEP SADWLATAAA RGRVEEVRAL LEAGALPNAP NSYGRRPIQV MMMGSARVAE LLLLHGAEPN CADPATLTRP VHDAAREGFL DTLVVLHRAG ARLDVRDAWG RLPVDLAEEL GHRDVARYLR AAAGGTRGSN HARIDAAEGP SDIPDGYGRK KRRQRRR
• Storage and Stability:May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.